Cantor Fitzgerald Reiterates a Buy Rating on Elevance Health (ELV), Keeps the PT

Core Viewpoint - Elevance Health, Inc. (NYSE:ELV) is considered one of the most undervalued long-term stocks to buy, with a Buy rating and a price target of $400 set by Cantor Fitzgerald [1]. Group 1: Earnings Outlook - Cantor Fitzgerald maintains a cautious outlook on the 2026 Medicaid environment, highlighting conservative elements in Elevance's earnings per share projections for that year [2]. - Execution in Medicare Advantage, commercial business, and Carelon is deemed critical for Elevance's performance in 2026 and 2027, especially given the increasing uncertainty surrounding Medicaid visibility [2]. Group 2: Segment Performance - Despite the cautious outlook, Cantor Fitzgerald believes Elevance Health will outperform expectations in the Medicare Advantage and Carelon segments [3]. - Elevance Health operates as a health insurer in the United States, providing a variety of health plans and services [3].